By Ben Hirschler BARCELONA (Reuters) - A new heart failure drug from Novartis cut the risk of both cardiovascular death and hospitalization by a fifth in a keenly awaited study, boosting hopes for a product that is seen as a multibillion-dollar seller. There has been little progress for more than a decade in treating chronic heart failure, in which the heart fails to pump enough blood around the body, so there is excitement about the new medicine among both doctors and investors. ESC officials flagged the PARADIGM-HF trial as one of the highlights of the five-day event in Barcelona, reflecting the pressing need to find better treatments than the current line-up of old generic medicines. “Everything has been pretty stalled in heart failure,” said Keith Fox, a cardiologist at the University of Edinburgh who also chairs the ESC's congress program committee. via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment